Provided by Tiger Trade Technology Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

31.27
-1.4200-4.34%
Post-market: 30.95-0.3200-1.02%19:47 EDT
Volume:2.20M
Turnover:69.74M
Market Cap:2.23B
PE:-10.05
High:33.05
Open:33.05
Low:31.08
Close:32.69
52wk High:94.90
52wk Low:25.59
Shares:71.31M
Float Shares:54.64M
Volume Ratio:1.35
T/O Rate:4.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1128
EPS(LYR):-2.3852
ROE:-20.21%
ROA:-14.95%
PB:1.65
PE(LYR):-13.11

Loading ...

Structure Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview

Reuters
·
May 05

Structure Therapeutics (GPCR) Is Down 7.2% After Strong Phase 2 Oral GLP‑1 Obesity Data – Has The Bull Case Changed?

Simply Wall St.
·
May 03

Structure Therapeutics presents Phase 2b ACCESS obesity trial data for aleniglipron at ADA 2026

Reuters
·
Apr 28

Structure Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
Apr 27

Structure Therapeutics initiated with a Buy at Canaccord

TIPRANKS
·
Apr 27

Structure Therapeutics announces annual general meeting webcast for shareholders

Reuters
·
Apr 24

Structure Therapeutics COO, GC Matthew Lang files initial beneficial ownership statement

Reuters
·
Apr 24

Is Septerna (SEPN) Quietly Redefining Its GPCR Strategy With This First-in-Human SEP-479 Trial?

Simply Wall St.
·
Apr 22

Press Release: AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Dow Jones
·
Apr 20

Is Structure Therapeutics (GPCR) Building a Legal-Led Edge in Its Obesity and Metabolic Pipeline Strategy?

Simply Wall St.
·
Apr 19

BRIEF-Structure Therapeutics Appoints Matthew Lang, J.D. As Chief Operating Officer And General Counsel

Reuters
·
Apr 15

Structure Therapeutics names Matthew Lang COO, general counsel

Reuters
·
Apr 15

Structure Therapeutics Appoints Matthew Lang, J.d. as Chief Operating Officer and General Counsel

THOMSON REUTERS
·
Apr 15

Septerna: Advancing GPCR Pipeline and Strategic Partnerships Support Buy Rating and $40 Price Target

TIPRANKS
·
Apr 14

Is Septerna (SEPN) Using Its First PTH1R Trial To Redefine Its GPCR Strategy?

Simply Wall St.
·
Apr 13